The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer

Inclusion Criteria:

* Patients diagnosed with prostate cancer that elect to undergo primary cryotherapy of the prostate
* Patients who are diagnosed with clinical stage T1a -T2c prostate cancer
* Gleason score sum of less than or equal to 7
* Prostate-specific antigen (PSA) \< 20 ng/dl
* Patient will read, understand and sign the informed consent and Health Insurance Portability and Accountability Act (HIPAA) agreement
* Patients must have a life expectancy of at least one year

Exclusion Criteria:

* Known hypersensitivity to granulocyte macrophage colony stimulating factor (GM-CSF) or yeast
* Anticipated blood donation within the next 90 days
* Magnetic resonance imaging (MRI), computed tomography (CT) and bone scan evidence of metastatic prostate cancer regardless the PSA level; (the indication for which is clinically driven and at the discretion of the treating physician)
* Any history of current or within the past 48 hours of acute or chronic bacterial, fungal or viral infectious disease
* Documented excessive leukemic myeloid blasts in the bone marrow or peripheral blood (\>= 10%) in the past 6 months
* Previous organ transplant
* Immunosuppression including primary, secondary, iatrogenic and idiopathic
* Other serious diseases (hematological, hepatic, renal, respiratory, central nervous system, autoimmune or psychiatric)
* Enrollment in other studies for any disease in the past 30 days
* Diagnosis of cancer that in not considered cured, except basal cell carcinoma (BCC) of skin
* Prior transurethral resection of the prostate with a large tissue defect (at the discretion of the investigator)
* History of abdominoperineal resection for rectal cancer, rectal stenosis, or other major rectal pathology
* Patient currently receiving lithium, steroid, chemotherapy or radiotherapy treatment
* Patients with a Hemoglobin of less than 12%